GlassScriptPhysician profile
Richard Tomm
NPI 1891891651
$9,742.03
in general payments reported to CMS, 2019-2025
44 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $1,400 · 2021: $1,613 · 2022: $1,521 · 2023: $1,498 · 2024: $1,237 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,062 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,062.32 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,856.86 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Amgen INC. | $1,114.78 | 2019-2025 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $844.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $554.29 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $519.53 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $454.46 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $361.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $332.47 | 2021-2024 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $324.77 | 2019-2024 | Ajovy, Austedo |
| Allergan, INC. | $313.45 | 2020 | |
| Glaxosmithkline, LLC. | $311.00 | 2020-2024 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $276.44 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $254.15 | 2019-2025 | Eliquis |
| Bausch Health US, LLC | $229.81 | 2019-2023 | Aplenzin |
| Radius Health, INC. | $222.05 | 2019-2025 | Tymlos |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $209.84 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $200.22 | 2022 | |
| Eisai INC. | $164.58 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $143.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $119.98 | 2020-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Exact Sciences Corporation | $95.33 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Seqirus USA INC | $82.37 | 2021-2025 | Flucelvax, Fluad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.12 | 2020-2022 | |
| Amarin Pharma, INC. | $63.12 | 2022 | |
| Lundbeck LLC | $60.78 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $60.35 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $53.61 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.92 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $48.38 | 2021 | |
| Sanofi Pasteur INC. | $40.05 | 2020-2023 | |
| Dexcom, INC. | $38.82 | 2023-2025 | Dexcom G6 Transmitter |
| Echosens North America, INC. | $37.59 | 2025 | Fibroscan |
| Philips North America LLC | $26.96 | 2023 | |
| Genentech USA, INC. | $26.35 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $21.65 | 2021 | |
| Foundation Medicine, INC. | $21.15 | 2023 | Foundationone Cdx |
| Halozyme INC | $17.81 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $17.31 | 2022 | |
| Ibsa Pharma INC. | $17.18 | 2022 | |
| Dynavax Technologies Corporation | $17.18 | 2022 | |
| Clarus Therapeutics INC. | $17.04 | 2021 | |
| Tolmar, INC. | $17.00 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.20 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $15.67 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Tomm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.